News
Calyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate Update
March 2, 2023
—Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4— —Current customer projects under development are...
Read More
Calyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC
February 15, 2023
Roseville, MN and SAN DIEGO– February 15, 2023 – Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus,...
Read More
Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company
January 17, 2023
– The merger will bring together the technology platforms and facilities of two pioneering companies to create a leader in...
Read More
Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil
November 18, 2022
ROSEVILLE, Minn., Nov. 18, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company announced today that it has successfully completed...
Read More
Calyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
November 17, 2022
ROSEVILLE, Minn., Nov. 17, 2022 /PRNewswire/ -- Calyxt, Inc (Nasdaq: CLXT) a plant-based synthetic biology focused on engineering sustainable ingredients for customers...
Read More